A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept(Eylea) in Subjects with Wet AMD
AMD
Innovative At-Home Testing May Offer New Option for Patients Managing Age-Related Macular Degeneration
When Paulette Quick was diagnosed with age-related macular degeneration (AMD), it came as a complete shock. As a former CPR instructor and amateur radio operator, she hadn’t noticed any symptoms. It was only after a …
Clinical Trial Offers Promising Therapeutic Option to Patients with Wet Age-Related Macular Degeneration
The Clinical Eye Research Unit (CERU) at the University of Wisconsin–Madison Department of Ophthalmology and Visual Sciences has been instrumental in the approval of a new treatment option for patients with exudative age-related macular degeneration (wet AMD).
Dr. Julie Mares retires after 32 years of research and service
Mares, a professor in the Department of Ophthalmology and Visual Sciences, retired from UW-Madison on July 14th after a lengthy career exploring the connections between food, a healthy lifestyle, genetics, and nutrition in preserving eye health.
7 Ways to Protect Your Eyes from Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is one of the leading causes of blindness over age 50, affecting about 2.1 million people nationwide. Early diagnosis and treatment are the keys to preventing vision loss. AMD is a …
Art, In Spite of AMD
Jefferey Lange is fascinated by the beauty and arrangement of colors and textures. As an artist diagnosed with age-related macular degeneration (AMD), Lange is acutely aware of being able to see colors and textures. Lange …
Fundus Photograph Reading Center Participates in New NIH Clinical Study
The Fundus Photograph Reading Center (FPRC) in the Department of Ophthalmology and Visual Sciences (DOVS) at the University of Wisconsin-Madison is the core imaging lab for a new international clinical study funded by the National …
CHROMA
A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration.